Literature DB >> 12552058

Toxic neuropathy in patients with pre-existing neuropathy.

V Chaudhry1, M Chaudhry, T O Crawford, E Simmons-O'Brien, J W Griffin.   

Abstract

The authors report significant worsening of a pre-existing neuropathy in six patients who received "non-toxic" dosages of known neurotoxic agents. Before treatment, baseline total neuropathy score (TNS) averaged 9.5 (range 0 to 19). After chemotherapy (Taxol [125 to 175 mg/m(2) x 4]; vincristine [2 to 5 mg]; cisplatin [40 mg/m(2) x 8]; and thalidomide [60 g]), the TNS averaged 22 (range 13 to 29). The authors conclude that functionally disabling toxic neuropathy can occur in patients with pre-existing neuropathy at standard doses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12552058     DOI: 10.1212/01.wnl.0000043691.53710.53

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  51 in total

1.  Exacerbation of Charcot-Marie-Tooth type 2E neuropathy following traumatic nerve injury.

Authors:  Eric Villalón; Jeffrey M Dale; Maria Jones; Hailian Shen; Michael L Garcia
Journal:  Brain Res       Date:  2015-09-28       Impact factor: 3.252

Review 2.  Inherited neuropathies: clinical overview and update.

Authors:  Christopher J Klein; Xiaohui Duan; Michael E Shy
Journal:  Muscle Nerve       Date:  2013-06-26       Impact factor: 3.217

3.  Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study.

Authors:  Tulay Kus; Gokmen Aktas; Mehmet Emin Kalender; Alper Sevinc; Seval Kul; Ali Suner; Esra Ulker; Celaletdin Camci
Journal:  Support Care Cancer       Date:  2015-08-18       Impact factor: 3.603

Review 4.  A framework for assessment in oncology rehabilitation.

Authors:  Laura S Gilchrist; Mary Lou Galantino; Meredith Wampler; Victoria G Marchese; G Stephen Morris; Kirsten K Ness
Journal:  Phys Ther       Date:  2009-01-15

Review 5.  Emerging trends in understanding chemotherapy-induced peripheral neuropathy.

Authors:  Jérémy Ferrier; Vanessa Pereira; Jérome Busserolles; Nicolas Authier; David Balayssac
Journal:  Curr Pain Headache Rep       Date:  2013-10

Review 6.  Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

Authors:  Wolfgang Grisold; Guido Cavaletti; Anthony J Windebank
Journal:  Neuro Oncol       Date:  2012-09       Impact factor: 12.300

7.  Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine.

Authors:  Jessica A Boyette-Davis; Juan P Cata; Larry C Driver; Diane M Novy; Brian M Bruel; Deidre L Mooring; Gwen Wendelschafer-Crabb; William R Kennedy; Patrick M Dougherty
Journal:  Cancer Chemother Pharmacol       Date:  2012-12-11       Impact factor: 3.333

Review 8.  Supportive care for patients with early breast cancer.

Authors:  Laura García-Estévez; Ignasi Tusquets; Isabel Alvarez; César Rodríguez; Yolanda Fernández; Miguel Angel Seguí; Jesús García-Mata; Ana Lluch
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

Review 9.  Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies.

Authors:  Allyson J Ocean; Linda T Vahdat
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

Review 10.  Long-term Toxicity of Cancer Treatment in Older Patients.

Authors:  Armin Shahrokni; Abraham J Wu; Jeanne Carter; Stuart M Lichtman
Journal:  Clin Geriatr Med       Date:  2015-10-13       Impact factor: 3.076

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.